Globus Medical Announces Acquisition of Robotics Developer KB Medical

Posted On August 2, 2017 By OrthoSpineNews In Robotics, Top Stories /  

AUDUBON, Pa., Aug. 02, 2017 (GLOBE NEWSWIRE) — Globus Medical, Inc. (GMED), a leading musculoskeletal solutions manufacturer, today announced that the acquisition of KB Medical, SA, a robotic developer based in Lausanne, Switzerland, closed during the second quarter of 2017.

“The acquisition of KB Medical demonstrates Globus Medical’s continued commitment and enthusiasm for the potential impact of robotic technology on surgery,” said Dave Demski, President, Emerging Technologies. “The addition of KB Medical will enable Globus Medical to accelerate, enhance and expand our product portfolio in Imaging, Navigation and Robotics. KB Medical’s experienced team of technology development professionals, its strong IP portfolio, and shared philosophy for robotic solutions in medicine strengthen Globus Medical’s position in this strategic area.”

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA.  The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders.

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms.  These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends.  Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted.  These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to successfully integrate the international operations acquired from Alphatec, both in general and on our anticipated timeline, our ability to transition Alphatec’s international customers to Globus Medical products, our ability to realize the expected benefits to our results from the Alphatec acquisition, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks.  For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission.  These documents are available at www.sec.gov.  Moreover, we operate in an evolving environment.  New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements.  Forward-looking statements contained in this press release speak only as of the date of this press release.  We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Read More
Group-Shot-with-TCS-2-11-15.jpg

Titan Spine Continues Strong Sales Performance with 49% YOY Growth Rate at Mid-Year 2017

Posted On August 2, 2017 By OrthoSpineNews In Spine, Top Stories /  

August 02, 2017

MEQUON, Wis.–(BUSINESS WIRE)–Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants, today announced that it continues its strong revenue acceleration for the second quarter of 2017, driven by the increasing demand for the Company’s nanoLOCK® surface technology. nanoLOCK® is the company’s next-generation surface technology featuring enhanced micro and nano-scaled architecture, proven to significantly improve the osteogenic response it creates.1

The company reports the following for the second quarter:

  • Surpassed 50,000 implantations of its Endoskeleton® interbody fusion devices since inception
  • nanoLOCK® sales volume has increased by 42% since the close of the first quarter
  • nanoLOCK® has been utilized to date by 150 surgeons in 98 hospitals
  • Achieved 2,500 implantations of nanoLOCK® since launch

Ted Bird, Chief Commercial Officer of Titan Spine, commented, “Following a record first quarter, we continued to exceed expectations during the second quarter for a strong close to the mid-2017 mark. The significant demand for nanoLOCK® is a direct reflection of our expanded sales team’s ability to reach more surgeons and surgeons’ recognition of the advantages our surface technology provides at the nano-cellular level for helping patients heal faster following spine fusion surgery. In fact, we have more than doubled the number of surgeon customers using nanoLOCK in the second quarter compared to the first. We are pleased that our second quarter achievements demonstrate a growing confidence and continued adoption of nanoLOCK®.”

Steve Cichy, Executive Vice President of Sales of Titan Spine, added, “The demand for nanoLOCK® has certainly fueled our significant sales growth over the first half of this year. We have recently invested significant capital to beef up our instrument set and implant inventory to meet this growing demand, which will start to pay dividends over the remainder of the year and beyond.”

Titan Spine offers a full line of Endoskeleton® titanium implants that feature its proprietary nanoLOCK® surface technology, which was launched in the U.S. in October 2016 following FDA clearance in late 2014. The nanoLOCK® surface technology consists of a unique combination of roughened topographies at the macro, micro, and nano levels (MMN™). This unique combination of surface topographies is designed to create an optimal host-bone response and actively participate in the fusion process by promoting the upregulation of osteogenic and angiogenic factors necessary for bone growth, encouraging natural production of bone morphogenetic proteins (BMPs), downregulating inflammatory factors, and creating the potential for a faster and more robust fusion.2,3,4 All Endoskeleton® devices are covered by the company’s risk share warranty.

About Titan Spine

Titan Spine, LLC is a surface technology company focused on the design and manufacture of interbody fusion devices for the spine. The company is committed to advancing the science of surface engineering to enhance the treatment of various pathologies of the spine that require fusion. Titan Spine, located in Mequon, Wisconsin and Laichingen, Germany, markets a full line of Endoskeleton® interbody devices featuring its proprietary textured surface in the U.S. and portions of Europe through its sales force and a network of independent distributors. To learn more, visit www.titanspine.com.

nanoLOCK® named the winner of Back Pain Centers of America’s 2017 Awards of Excellence for the Technology Innovation Award

1 Olivares-Navarrete, R., Hyzy S.L., Gittens, R.A., Berg, M.E., Schneider, J.M., Hotchkiss, K., Schwartz, Z., Boyan, B. D. Osteoblast lineage cells can discriminate microscale topographic features on titanium-aluminum-vanadium surfaces. Ann Biomed Eng. 2014 Dec; 42 (12): 2551-61.

2 Olivares-Navarrete, R., Hyzy, S.L., Slosar, P.J., Schneider, J.M., Schwartz, Z., and Boyan, B.D. (2015). Implant materials generate different peri-implant inflammatory factors: PEEK promotes fibrosis and micro-textured titanium promotes osteogenic factors. Spine, Volume 40, Issue 6, 399–404.

3 Olivares-Navarrete, R., Gittens, R.A., Schneider, J.M., Hyzy, S.L., Haithcock, D.A., Ullrich, P.F., Schwartz, Z., Boyan, B.D. (2012). Osteoblasts exhibit a more differentiated phenotype and increased bone morphogenetic production on titanium alloy substrates than poly-ether-ether-ketone. The Spine Journal, 12, 265-272.

4 Olivares-Navarrete, R., Hyzy, S.L., Gittens, R.A., Schneider, J.M., Haithcock, D.A., Ullrich, P.F., Slosar, P. J., Schwartz, Z., Boyan, B.D. (2013). Rough titanium alloys regulate osteoblast production of angiogenic factors. The Spine Journal, 13, 1563-1570.

Contacts

Company:
Titan Spine
Andrew Shepherd, 866-822-7800
ashepherd@titanspine.com
or
Media:
The Ruth Group
Kirsten Thomas, 508-280-6592
kthomas@theruthgroup.com

Read More
prod_osteo_allofuse-fibers-boat_split_510x330.jpg

AlloSource Releases AlloFuse Line Extension

Posted On August 1, 2017 By OrthoSpineNews In Biologics, Top Stories /  

CENTENNIAL, Colo., Aug. 1, 2017 /PRNewswire-USNewswire/ — AlloSource, one of the nation’s largest providers of cartilage, bone, skin, soft-tissue, and cellular allografts to advance patient healing in surgical procedures and wound care, today announced the release of AlloFuse® Select CM, a premium addition to AlloSource’s AlloFuse portfolio.

AlloFuse Select CM combines osteoconductive, osteoinductive, and osteogenic properties to initiate and nurture bone growth, delivering the benefits of autograft bone without the potential drawbacks. The product is clinically proven to activate and support bone formation and can be used in a variety of spinal, neurologic, and orthopedic procedures. This cellular allograft matrix also has good handling characteristics, as it is moldable and compressible for insertion into interbody implants or placement around anatomical structures.

“AlloFuse Select CM underscores our commitment to offering surgeons the advanced solutions they need to support their patients’ healing,” said Kerr Holbrook, AlloSource Chief Commercial Officer. “Our passion for our donors and recipients is reflected in the continued expansion of the regenerative therapies we provide.”

The addition of AlloFuse Select CM enhances the AlloFuse portfolio of demineralized bone fiber, putty, paste, and gel allografts. This line expansion provides surgeons with a premium AlloSource cellular allograft to meet a variety of needs for patients.

About AlloSource

AlloSource is one of the largest nonprofit cellular and tissue networks in the country, offering more than 200 types of precise cartilage, cellular, bone, skin and soft-tissue allografts to advance patient healing. For more than 20 years, AlloSource’s products have bridged the proven science of allografts with the advanced technology of cells, offering life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. As the world’s largest processor of cellular bone allografts, fresh cartilage tissue for joint repair and skin allografts to help patients heal from severe burns, AlloSource delivers unparalleled expertise and service to its growing network of surgeons, partners, and the country’s most reputable organ procurement organizations. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org or our educational website, allograftpossibilities.org.

Media Contact
Megan Duggan
AlloSource
720. 382. 2766
mduggan@allosource.org

 

SOURCE AlloSource

Read More
rea-medicrea-5a4276cf1b952a23a2381b1b66a95324546377b474c62e264272afb9a3c02711.jpg

Medicrea Announces World’s First Minimally-Invasive Spine Surgery Using Patient-Specific Implants

Posted On August 1, 2017 By OrthoSpineNews In Spine, Top Stories /  

July 31, 2017

LYON, France & NEW YORK–(BUSINESS WIRE)–The Medicrea Group (Euronext Growth Paris: FR0004178572 – ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered device design and manufacturing with UNiD™ ASI technology, announced today that the world’s first minimally-invasive spine surgery using patient-specific implants was performed by Dr. C.J. Kleck at the University of Colorado Hospital using the company’s UNiD™ MIS Rod.

The limited visualization of the spine associated with Minimally-Invasive Spine (MIS) techniques poses unique challenges for surgeons whose goal is segmental sagittal balance, while offering known benefits to patients which include reduced muscle damage during surgery and improved recovery time post-operatively. Such advantages have led MIS solutions to be an area of particular growth in the spine market. Surgeons trained in MIS techniques are able to treat a growing number of spinal conditions due to recent advancements in imaging and device offerings. The UNiD™ MIS Rod is the first and only spinal implant in the world that is manufactured specially for the patient prior to minimally-invasive surgery. The UNiD™ MIS Rod is compatible with percutaneous and mini-open MIS applications, removing the need to modify implants intra-operatively.

“As one of the early adopters of UNiD™ ASI, I have seen firsthand the associated benefits of the technology in open deformity cases. I am pleased to extend it now to my MIS cases where I see the potential for increased utility in degenerative indications.” stated Dr. Kleck following the surgery. “With each patient-specific implant designed utilizing Medicrea’s support services, machine learning and predictive analytics, my colleagues and I have seen an improved efficiency in our pre-surgical as well as our surgical practice. I believe this scientific, data-driven model is the best approach available to optimize long-term patient results and represents the future of value-based spinal care.”

Denys Sournac, President and CEO of Medicrea, stated, “We are now able to respond to the growing demand for personalized UNiD™ ASI technology in minimally-invasive surgery by introducing the UNiD™ MIS Rod to our UNiD™ TEK line of FDA-cleared patient-specific implants. We are the only company in Spine able to generate Adaptive Spine Intelligence powered by proprietary data science and remain committed to driving improved outcomes and efficiencies for patients, surgeons, hospitals and payers with our platform of UNiD™ ASI implants, services and IT.”

Today, more than 1,500 UNiD™ Rod surgeries have been performed worldwide. The range of patient-specific implants available as UNiD™ TEK are fully compatible with Medicrea’s platform of innovative procedurally-integrated solutions.

About Medicrea (www.Medicrea.com)

Through the lens of predictive medicine, Medicrea leads the design, integrated manufacture, and distribution of 30+ FDA approved spinal implant technologies that have been utilized in over 100,000 spinal surgeries to date. By leveraging its proprietary software analysis tools with big data and machine learning technologies and supported by an expansive collection of clinical and scientific data, Medicrea is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.

Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 175 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.

For further information, please visit: Medicrea.com.

Connect with Medicrea:
FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

Medicrea is listed on
EURONEXT Growth Paris
ISIN: FR 0004178572
Ticker: ALMED

Contacts

Medicrea
Denys Sournac
Founder, Chairman and CEO
dsournac@Medicrea.com
or
Fabrice Kilfiger,
Chief Financial Officer
fkilfiger@Medicrea.com
Tel: +33 (0)4 72 01 87 87

Read More

Samumed’s Osteoarthritis Research Selected for an Oral Presentation at a Gordon Research Conference

Posted On August 1, 2017 By OrthoSpineNews In Biologics, Top Stories /  

August 01, 2017

SAN DIEGO–(BUSINESS WIRE)–Samumed, a leader in Wnt research and development, has been selected for an oral presentation at the 2017 Gordon Research Conference, “Wnt Signaling: A Pathway Implicated in Animal Development, Stem Cell Control and Cancer,” to be held in Stowe, Vermont on August 6-11, 2017.

“We are excited to be presenting at the prestigious Gordon Research Conference, which provides an international forum for the discussion of cutting-edge research in life sciences,” said Dr. Yusuf Yazici, Samumed’s Chief Medical Officer. “The preclinical research that formed the basis of our promising investigational drug for the treatment of osteoarthritis is an example of how innovative science can translate into clinical benefit.”

Samumed’s presentation, “Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis,” will be available on the company website after the conference at: http://bit.ly/2hhTp68.

About Gordon Research Conferences

Gordon Research Conferences is an organization that coordinates renowned international scientific conferences dedicated to advancing the frontiers of scientific research in the biological, chemical, and physical sciences, and their related technologies. To attend a meeting, scientists must apply to that respective research conference. The conference chair carefully considers every applicant and hand-selects 200 attendees for each conference. Further information can be found at: https://www.grc.org.

About Samumed, LLC

Based in San Diego, CA, Samumed (www.samumed.com) is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and innovation. Samumed has discovered new targets and biological processes in the Wnt pathway, allowing the team to develop small molecule drugs that potentially address numerous degenerative conditions as well as many forms of cancer.

Contacts

For Samumed
Chrissy Randall, 202-393-7337
crandall@brunswickgroup.com

Read More
1-1-2.jpeg

Spartan Medical Purchases 7D Surgical Technology to Support Its Commercialization Efforts in The Key Mid-Atlantic Hospital Market

Posted On July 31, 2017 By OrthoSpineNews In Spine, Top Stories /  

TORONTO, July 31, 2017 /PRNewswire/ — 7D Surgical, developer of ground breaking surgical navigation technologies, announced today that Spartan Medical has purchased the 7D Surgical System to support its strategic sales plan in Maryland, Washington D.C. and Virginia.  7D Surgical has entered into an exclusive sales representative agreement with Spartan Medical for many of the premier medical facilities within those markets.

“Our new partnership with Spartan Medical is another important step in our rapid growth strategy in North America,” said Beau Standish, Chief Executive Officer of 7D Surgical.  “Their expertise and unique relationships with federal facilities will be critical in bringing the most advanced machine-vision based navigation technologies to DoD spine surgeons and the U.S. military personnel and veterans they serve.”

The 7D Surgical System is the first and only Machine-Vision Image Guided Surgery (MvIGS) platform. For the first-time spine surgery patients can be automatically registered using only visible light in just seconds with 7D Surgical’s Flash™ Registration technology. Unlike time-consuming conventional image guided surgery (IGS) systems that depend on intraoperative radiation, this new MvIGS platform can achieve an incredibly fast surgical workflow for spine procedures.  Continuing to leverage the capabilities of machine-vision, 7D Surgical’s soon to be released Flash™ Fix technology can also update and correct the registration at any time during the procedure in just seconds.

“To me, this is similar to the invention of the X-ray,” said Vince Proffitt, President of Spartan Medical.  “Those of us that have been in surgeries supporting our implants know the real challenges of accurate and reproducible imaging and navigation.  We know how dependent the surgery may be on the equipment technicians’ skills and training, and we also know the incredible risks of daily radiation. The 7D Surgical System eliminates these critical concerns and creates a surgeon controlled, real-time, radiation-free, simple and accurate imaging and navigation system…truly a technological marvel!”

Live demonstrations of the 7D Surgical System are available at Spartan Medical Headquarters in Silver Spring, Maryland.  Contact Spartan Medical to schedule a time to experience the system in action at 1-888-240-8091, or email Spartan Medical at 170185@email4pr.com.

About 7D Surgical
7D Surgical is a privately-owned Toronto based company that develops advanced optical technologies and machine vision-based registration algorithms to improve surgical workflow and patient care. 7D Surgical’s flagship FDA 510(k)-cleared and Health Canada-approved MvIGS system delivers profound improvement to surgical workflows in spine surgery, providing the promise of similar future advancements in other surgical specialties.  www.7Dsurgical.com

Flash™ Fix: http://7dsurgical.com/7d-surgical-system/flash-technology/

Contact:
Beau Standish, CEO
7D Surgical
+1 647 484-0078
www.7Dsurgical.com
170185@email4pr.com

About Spartan Medical

Spartan Medical Inc. was founded in 2008 by a former Air Force Intelligence Officer to provide an extensive armamentarium of advanced medical devices and technologies focused on the needs of the VA and DoD surgeon.  Spartan Medical is considered a top priority vendor in the VA as a certified Service-Disabled Veteran-Owned Small Business (SDVOSB), and has secured multi-year Blanket Purchase Agreements at 30 major military treatment facilities.  With a core staff possessing over 200 years of combined expertise and experience in the field, and numerous highly trained and skilled consultants across the nation, Spartan Medical assures no single points of failure.  Consistent with its mission to provide the best products and services to our nation’s wounded warriors and veterans, Spartan Medical has recently collaborated with 7D Surgical to provide the most innovative, state-of-the-art, image-guided spinal navigation system – with zero radiation –  to meet the incredible need to improve implant placement accuracy in real-time while eliminating radiation in the operating room.

Contact:
Vince Proffitt, President
Spartan Medical Inc.
+1 888 240 -8091
www.spartanmedspine.com
170185@email4pr.com

Forward-looking Statements

This press release contains forward-looking statements regarding, among other things, statements pertaining to expectations, goals, plans, objectives, and future events. 7D Surgical intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, and the Private Securities Reform Act of 1995. In some cases, forward-looking statements can be identified by the following words: “may,” “can,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “promise,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions, and other factors that may cause actual results to differ materially from those indicated by forward-looking statements, many of which are beyond 7D Surgical’s ability to control or predict. Given these uncertainties, undue reliance should not be placed on these forward-looking statements. 7D Surgical does not undertake any obligation to release publicly any updates or revisions to these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

“Flash,” as well as the “7D” logo, whether standing alone or in connection with the words “7D Surgical” are protected trademarks of 7D Surgical.

SOURCE 7D Surgical Inc.

Related Links

http://7dsurgical.com

Read More
NuVasive_1_Full.jpg

NuVasive Announces New Organizational Structure To Drive Growth And Profitability Goals

Posted On July 27, 2017 By OrthoSpineNews In Spine, Top Stories /  

SAN DIEGO, July 27, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced a new organizational structure to drive the Company’s growth and profitability goals, supporting its strategy to help deliver safer, more predictable spine surgery.

“As the innovation pioneer and largest, pure-play spine technology company, NuVasive continues to deliver significant value to its customers and shareholders,” said Gregory T. Lucier, NuVasive’s chairman and chief executive officer. “With incredible opportunities ahead, we are taking steps to refine the company’s operating structure to tightly align strategy, product development and marketing and integrate our global commercial channels, while scaling global operations to best address the growing needs of our partners and patients.”

Today the Company announced that Jason Hannon, president and chief operating officer, is stepping down from his position to pursue other interests. He will remain with NuVasive through the end of the year in an advisory capacity. During Mr. Hannon’s successful 12-year career at NuVasive, he has made countless important contributions to the Company. In connection with Mr. Hannon’s departure, the Company has accelerated its timeline to implement organizational changes that will position NuVasive to execute against the Company’s strategic goals. Effective August 1, the Company will:

  • Align strategy, technology and marketing to build a world-class product development and commercialization capability;
  • Integrate its U.S. Commercial and International sales functions into a scalable global commercial organization; and
  • Transform global operations to drive operational efficiencies through the combination of manufacturing, supply chain, information technology (IT), regulatory affairs and quality assurance (RA/QA).

Matt Link, president, U.S. Commercial is being promoted to a key leadership role as executive vice president, Strategy, Technology and Corporate Development, a newly created position to further drive the Company’s innovation agenda. Mr. Link is a long-tenured NuVasive executive with more than 15 years of industry experience, including extensive knowledge of the U.S. spine marketplace, as well as surgeon and hospital dynamics. In this role, he will lead product and systems development, global marketing, surgeon education, clinical research and corporate development. Mr. Link’s experience in surgeon requirements and commercial operations will be key as NuVasive continues to bring leading innovation to market.

Skip Kiil, executive vice president, International is named executive vice president, Global Commercial. Mr. Kiil joined NuVasive in June and has more than 15 years of experience as a global medical technologies and life sciences business leader. He was previously with Alcon, a division of Novartis Corporation, where he most recently served as surgical head, Europe, Middle East, Africa and Russia. He is a proven leader in managing and growing complex, global commercial enterprises internationally and domestically within the healthcare and spine technology industries. His strategic and operational expertise in market entry and development are critical as NuVasive seeks to double its International market share in the coming years and further expand the Company’s position in the U.S. marketplace.

Steve Rozow, vice president, Global Operations, assumes an elevated role as executive vice president, Global Process Transformation, including IT and RA/QA, in addition to his current Global Operations responsibilities. Since joining NuVasive in 2015, Mr. Rozow has led improvements in supply chain and fulfillment, as well as the successful development of the Company’s new manufacturing facility in West Carrollton, Ohio. Mr. Rozow is an experienced medical device leader including more than 20 years with Zimmer, where he served in various manufacturing and operational leadership roles. His position is critical as the Company focuses on scaling global operations and driving operational improvement initiatives.

Unrelated to the organizational updates announced today, the Company has accepted the resignation of its chief financial officer, Quentin Blackford, effective August 25, 2017. Mr. Blackford is pursuing another opportunity outside the spine industry and has agreed to remain with the company during this transition period. Mr. Blackford’s resignation is not the result of any dispute or disagreement with NuVasive, including any matters relating to the Company’s accounting practices or financial reporting. Vickie Capps, in her role as an independent member of NuVasive’s board of directors and a member of the audit committee, will provide guidance and support to the Company’s financial organization during the transition period. Ms. Capps is a well-respected financial executive, having served as CFO of DJO Global, as well as CFO of several public and private companies. Ms. Capps will also assist the Company in its search for a successor to Mr. Blackford.

“Since becoming CEO over two years ago, I have been working with our board to build a world-class leadership team to support our revenue growth and profitability goals. Together, we are executing against our 5-year strategic plan and building a deep bench of talent, positioning us well to execute against our short- and long-term initiatives. I remain more confident than ever in our Company’s position to take on the next $1 billion in growth,” said Lucier.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is transforming spine surgery and beyond with minimally invasive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com

Read More
enza_cropped_2.jpg

Camber Spine Technologies Announces Exceeding the 150th Implantation of ENZA™ Zero-Profile ALIF

Posted On July 27, 2017 By OrthoSpineNews In Spine, Top Stories /  

WAYNE, Pa., July 27, 2017 /PRNewswire/ — Camber Spine Technologies, today announced that they have exceeded 150 implantations of the ENZA™ Zero-Profile ALIF device that was launched last July.

“We have been doing anterior spine reconstructions for over 20 years and have used a lot of different ALIF devices,” said Orthopedic Surgeon, Dr. Steven B. Wolf, M.D. of OIP in Camp Hill, PA. “I have extensive experience using the Globus Independence®, Zimmer-LDR ROI-A® and other ALIF devices from Renovis and Titan Spine.  The ENZA™ has been an indispensable alternative to all those implants. I can insert ENZA™ and deploy fixation with one instrument and I have the reassurance that I can easily remove it if needed. With the insertion of ENZA™ the patient’s spine feels immediate stabilization, especially if they need to be flipped for posterior instrumentation. Our access surgeon loves this implant, because it makes his job much easier. ENZA’s™ single instrument deployment, without extra retraction of the vessels, eliminates the need for passing multiple locking instrumentation required by other devices.”

ENZA™ was designed to increase patient safety by minimizing retraction necessary for implantation of the device, utilizing its integrated fixation. It is often described as “designed for the access surgeon” because of its completely inline instrumentation–which relieves the burden that other systems induce by requiring larger retraction to accommodate angled instrumentation.

“We are very excited to achieve this important milestone in the initial launch of the ENZA™ ALIF,” said Daniel Pontecorvo, Camber Spine’s CEO. The overwhelming interest and success of ENZA™ reaffirms our plan to make this the first of an entire platform of products utilizing our patented ENZA™ Duo Presa™ (Two Grips) Anchor Technology. Surgeons assert that it is a simpler, safer and more stable alternative to all other locking ALIF devices.”

This achievement comes at an inflexion point for Camber Spine, as they continue to expand sales into new territories of the U.S with new hires.

The Camber Spine Technologies ENZA™ MIS Zero-Profile Anterior Interbody Fusion is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These implants may be implanted via a laparoscopic or an open anterior approach. The Camber Spine Technologies’ ENZA™ MIS Zero-Profile ALIF is intended to be used with additional FDA-cleared supplementary fixation systems.

About Camber Spine

Camber Spine Technologies, LLP, is a fast-growing musculoskeletal implant company founded in 2010 bringing innovative, best-in-class products to the market, providing surgeons and their patients with better treatment options. The company is committed to delivering surgeon inspired new technologies to the spine market. Camber is an ISO 13485 certified medical device company. Camber Spine Technologies, located in Wayne, Pennsylvania, markets a line of proprietary musculoskeletal products nationwide through its exclusive distributor, S1 Spine. For further information please visit www.cambermedtech.com . For inquiries about ENZA® or distribution opportunities please call 484.427.7060.

All of Camber Spine Technologies’ products are proudly MADE IN THE USA.

SOURCE Camber Spine Technologies

Read More
Bedford_Office-1.jpg

Anika Announces Appointment of Joseph Darling as President

Posted On July 27, 2017 By OrthoSpineNews In Biologics, Top Stories /  

July 27, 2017

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced the appointment of Joseph Darling, an orthopedic and medical device veteran with broad commercial experience, to the role of President. For the past 15 years, the Company’s Chief Executive Officer (CEO), Dr. Charles H. Sherwood served as President and plans to transition the role to Mr. Darling, while continuing his tenure as CEO. Mr. Darling brings more than 20 years of executive management and leadership experience from publicly-traded, commercial-stage companies including Baxter Healthcare, Smith & Nephew, ConMed, and Wyeth-Ayerst.

“Anika is at the cusp of a transformation. We are ushering in the next decade of growth through the build-out of a direct commercialization capability, a steady march of global expansion, and a pipeline that includes multiple potential blockbuster products,” said Charles H. Sherwood, Ph.D., Chief Executive Officer of Anika Therapeutics. “With his established track record overseeing global sales and marketing efforts at leading medical device companies, Mr. Darling is uniquely suited to help drive continued growth and spearhead Anika’s direct commercialization initiative. The company’s leadership team and our Board are excited for Mr. Darling to bring his deep expertise to the table during this exciting period.”

Most recently, Mr. Darling held executive leadership positions with two small privately held orthopedic companies. Prior to these roles, Mr. Darling held senior level executive positions at ConMed Corporation, a global, publicly-held, diversified medical device company, as Global President of its wholly-owned subsidiary, Linvatec Corporation, and as Executive Vice President of Global Corporate Commercial Operations. At ConMed, Mr. Darling led five global business units with $760 million in annual revenues and refocused organizational efforts in sales, marketing, and R&D.

“Dr. Sherwood and his leadership team have built Anika into an innovative, high growth, profitable, and global orthopedic company with a diversified portfolio that includes differentiated, market-leading therapeutic products and an emerging orthopedic medicine pipeline with tremendous potential,” said Mr. Darling. “I’m excited to join Anika during, what I believe to be, a pivotal moment in its 25-year history. My extensive commercial operations background in the orthopedic sector will prove to be integral to executing the company’s long-term growth strategy.”

Before ConMed, Mr. Darling was Senior Vice President and General Manager for the sports medicine business at Smith & Nephew and played an important role in defining a global strategy that propelled the company to a leadership position in the sports medicine field. Mr. Darling launched his career at Abbott Laboratories and Wyeth-Ayerst Pharmaceuticals, where he held management positions in sales and marketing before joining Baxter Healthcare as a Vice President of marketing and health systems. Mr. Darling holds a Bachelor of Arts in Political Science from Syracuse University. Click HERE to view Mr. Darling’s full bio.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST®, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

Forward-Looking Statements

The statements made in the first and second sentences of the second paragraph of this press release, which are not statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to the Company’s direct commercial capability, global expansion efforts, and the strength of the Company’s product pipeline. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks, uncertainties, and other factors. The Company’s actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company’s ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company’s ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company’s research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company’s clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company’s ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company’s ability to provide an adequate and timely supply of its products to its customers; and (x) the Company’s ability to achieve its growth targets. Additional factors and risks are described in the Company’s periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC’s website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.

Contacts

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer
or
For Media Inquiries:
Pure Communications
Sonal Vasudev, 917-523-1418
sonal@purecommunicationsinc.com

Read More
titan-spine-7x4.jpg

Back Pain Centers of America Announces Titan Spine as the Winner in the Awards of Excellence, “Technology Innovation” Category

Posted On July 27, 2017 By OrthoSpineNews In Spine, Top Stories /  

ATLANTA, GA (PRWEB) JULY 25, 2017

Back Pain Centers of America (BPC), which connects people searching for solutions to their neck and back pain with a reputable physician in their area, announces that Titan Spine’s nanoLOCK® Surface Technology is the winner of the 2017 Awards of Excellence for the Technology Innovation Award. This award is one of three categories of awards being presented in our 2017 series. The technology innovation award recognizes the top innovations advancing the field of orthopedic medicine.

The nanoLOCK® surface technology is a proprietary combination of textures at the macro, micro, and nano scales (MMN™) that has been shown to upregulate a significantly greater amount of bone growth factors necessary for fusion as compared to polyetheretherketone (PEEK), smooth titanium, and the company’s current titanium roughened surface. It is the next generation of the company’s current surface technology that has been implanted in patients since 2006.

“We are delighted to receive this award from Back Pain Centers of America,” said Andrew Shepherd, vice-president of marketing for Titan Spine. “Our nanoLOCK surface technology was developed with the goal of helping patients heal faster following back fusion surgery by interfacing with the patient’s cells at the nano level. We are pleased for the recognition it has generated.”

“We created this award category to recognize innovation and advances in medicine and technology,” said Brent Wheeler, president of Back Pain Centers of America. “We applaud Titan Spine for their innovation in taking spinal fusion procedures to the next level.”

More information about Titan Spine’s nanoLOCK® Surface Technology can be found at this link.

About Back Pain Centers of America
Back Pain Centers of America (BPC) has helped people find safe, reliable relief for chronic pain since 2009. The call centers match patients searching for relief for neck and back pain to reputable, board-certified healthcare practices in their geographic area. BPC has the largest network of minimally-invasive spine centers in America. This service is free to patients. For more information, please visit http://www.backpaincenters.com. Also follow BPC on LinkedIn, Facebook, or Twitter.

Read More